A Phase 2 interventional study of 400 ug Brimonidine Implant and 200 ug Brimonidine Implant in Glaucoma, Open-Angle, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.
Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2008, is one of 2 in phase 2, and was the 6th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
By country, each count listing its studies:
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 120 across the 17 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 31st largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 2, and was the 6th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, from their registry updates:
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Drug: 400 ug Brimonidine Implant
200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Drug: 200 ug Brimonidine Implant
Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Drug: Sham (no implant)
400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Also known as: Brimonidine Tartrate PS DDS®
200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Also known as: Brimonidine Tartrate PS DDS®
Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Percentage of Patients With a Visual Field Improvement in the Study Eye
Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.
Time frame: Baseline, Month 6
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Time frame: Baseline, Month 6
| Milestone | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Started | 25 | 21 | 24 |
| Completed | 25 | 19 | 24 |
| Not completed | 0 | 2 | 0 |
Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.
| Percentage of Patients | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Percentage of Patients With a Visual Field Improvement in the Study Eye | 12.0 | 9.5 | 4.2 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
| Number of Letters Read Correctly | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Baseline | 76.0 ± 7.82 | 80.6 ± 6.20 | 77.3 ± 7.71 |
| Change from Baseline at Month 6 | 2.8 ± 3.68 | -2.2 ± 18.35 | 0.3 ± 5.18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 ug Brimonidine Implant | — | 3/25 (12%) | 18/25 (72%) |
| 200 ug Brimonidine Implant | — | 5/21 (23.8%) | 19/21 (90.5%) |
| Sham (no Implant) | — | 1/24 (4.2%) | 20/24 (83.3%) |
| Event | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Arteriospasm coronaryCardiac disorders | 0/25 | 1/21 | 0/24 |
| CataractEye disorders | 0/25 | 1/21 | 0/24 |
| ConcussionInjury, poisoning and procedural complications | 0/25 | 1/21 | 0/24 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/25 | 1/21 | 0/24 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 1/21 | 0/24 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/25 | 0/21 | 1/24 |
| CellulitisInfections and infestations | 1/25 | 0/21 | 0/24 |
| SyncopeNervous system disorders | 1/25 | 0/21 | 0/24 |
| HypertensionVascular disorders | 1/25 | 0/21 | 0/24 |
| Event | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 6/25 | 2/21 | 3/24 |
| Punctate keratitisEye disorders | 4/25 | 2/21 | 1/24 |
| HeadacheNervous system disorders | 4/25 | 1/21 | 0/24 |
| Conjunctival HyperaemiaEye disorders | 3/25 | 3/21 | 3/24 |
| SinusitisInfections and infestations | 1/25 | 2/21 | 3/24 |
| CataractEye disorders | 0/25 | 1/21 | 3/24 |
| Intraocular pressure increasedInvestigations | 3/25 | 2/21 | 2/24 |
| HypertensionVascular disorders | 3/25 | 2/21 | 0/24 |
| Eye IrritationEye disorders | 3/25 | 0/21 | 2/24 |
| Eye PainEye disorders | 3/25 | 1/21 | 0/24 |
| Age, Customized(Participants) | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) | Total |
|---|---|---|---|---|
| <45 years | 0 | 0 | 1 | 1 |
| Between 45 and 65 years | 9 | 11 | 12 | 32 |
| >65 years | 16 | 10 | 11 | 37 |
| Sex: Female, Male(Participants) | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) | Total |
|---|---|---|---|---|
| Female | 12 | 12 | 10 | 34 |
| Male | 13 | 9 | 14 | 36 |
| Mean Deviation from Normal Visual Field Using the HFA 24-2(Decibels (db)) | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) | Total |
|---|---|---|---|---|
| Mean | -15.5 ± 5.26 | -14.6 ± 3.67 | -17.9 ± 5.09 | -16.0 (-30.9 to -6.4) |
The record gives a start of Sep 2008, a primary completion of Jan 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 2 years 3 months after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine